Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies–one targeting epidermal growth factor receptor (EGFR), the other programmed cell death 1 (PD-1). This dual treatment aims to supercharge the immune system, showing early signs of improving survival and response rates. For patients with no other treatment options, this breakthrough offers a glimmer of hope, potentially changing the trajectory of their fight against cancer.
https%3A%2F%2Fwww.newswise.com%2Farticles%2Ftackling-tough-cancers-the-dual-targeted-attack-on-metastatic-colorectal-cancer%2F%3Fsc%3Drsla
Tackling Tough Cancers: The Dual-Targeted Attack on Metastatic Colorectal Cancer
